A
Akihiko Gemma
Researcher at Nippon Medical School
Publications - 373
Citations - 15091
Akihiko Gemma is an academic researcher from Nippon Medical School. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 47, co-authored 345 publications receiving 12972 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Masahiro Seike,Akiteru Goto,Tetsuya Okano,Tetsuya Okano,Elise D. Bowman,Aaron J. Schetter,Izumi Horikawa,Ewy Mathé,Jin Jen,Ping Yang,Haruhiko Sugimura,Akihiko Gemma,Shoji Kudoh,Carlo M. Croce,Curtis C. Harris +14 more
TL;DR: Aberrantly increased expression of miR-21, which is enhanced further by the activated EGFR signaling pathway, plays a significant role in lung carcinogenesis in never-smokers, as well as in smokers, and is a potential therapeutic target in both EGFR-mutant and wild-type cases.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.
Journal ArticleDOI
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue,Kunihiko Kobayashi,Kazuhiro Usui,Makoto Maemondo,Shoji Okinaga,Iwao Mikami,Masahiro Ando,Koichi Yamazaki,Yasuo Saijo,Akihiko Gemma,Hitoshi Miyazawa,Tomoaki Tanaka,Kenji Ikebuchi,Toshihiro Nukiwa,Satoshi Morita,Koichi Hagiwara +15 more
TL;DR: This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib, and examination of EGFR mutations as a biomarker is recommended in this patient population.
Journal ArticleDOI
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito,Tatsuro Fukuhara,Naoki Furuya,Kana Watanabe,Shunichi Sugawara,Shunichiro Iwasawa,Yoshio Tsunezuka,Ou Yamaguchi,Morihito Okada,Kozo Yoshimori,Ichiro Nakachi,Akihiko Gemma,Koichi Azuma,Futoshi Kurimoto,Yukari Tsubata,Yuka Fujita,Hiromi Nagashima,Gyo Asai,Satoshi Watanabe,Masaki Miyazaki,Koichi Hagiwara,Toshihiro Nukiwa,Satoshi Morita,Kunihiko Kobayashi,Makoto Maemondo +24 more
TL;DR: A phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis of the NEJ026 trial, which established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC.